Smooth Drug Development February 2025 News Release

Monthly News – February 2025

At Smooth Drug Development, we are excited to share the latest updates and achievements from February 2025:

New Projects

We are delighted to announce several new collaborations:

• We are signing supply agreements for pembrolizumab and nivolumab trials.

Clinical and Scientific Departments News:

Our clinical teams continue to deliver outstanding progress:

• The CTA submission in Belarus was successfully performed for the Laronidase trial.
• Our team performed close-out visits in the Nimesulide trial.
• Site closures were completed for the Bempedoic acid trials (fed and fasting conditions).
• 112 patients were enrolled in the Pembrolizumab trial.

Business Development News:

Our Business Development team ended the year with active participation in key industry events:

• Our Medical Writing and Corporate Development team participated in a 3-day meeting in Hungary with a biotech company, discussing drug development programs in neurology, oncology, and inflammatory diseases across Europe and EAEU.
• Our team attended the Drug Development and Registration Conference in Moscow.
• The Business Development team attended the Clinical Trials Summit in Pakistan, where they held strategic discussions with the CEO of a Chinese Biotech company. The team also engaged with key stakeholders, including Pakistani regulators, WHO EMRO representatives, executives from Abbott (EU), GSK, Novartis, as well as local pharmaceutical companies, clinical sites, and CRO personnel